National Cancer Inst
National Cancer Institute (NCI) Extends Long-Standing Partnership with Inspirata
29 sept. 2020 10h26 HE | Inspirata, Inc.
Tampa, Florida, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Inspirata announced today the renewal of its long-standing partnership with the National Cancer Institute (NCI). Building on almost two decades of...
LIXTE.jpg
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
30 avr. 2020 10h30 HE | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, April 30, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the National Cancer Institute (NCI) and National Institute of...
LIXTE.jpg
First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors
04 déc. 2019 09h35 HE | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the National Cancer Institute (NCI) has enrolled the first two patients of a...
LIXTE.jpg
First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome
18 juil. 2019 09h35 HE | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, July 18, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the first patient has been enrolled in its Phase 1b/2 study of the safety and...
LIXTE.jpg
Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors
15 mai 2019 09h35 HE | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, May 15, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced the opening of a pharmacologic study of the ability of its lead clinical compound,...
Jack D. Sobel, M.D.
Karmanos Cancer Institute presents 25th Annual Partners Night Friday, Sept. 21, at historic Michigan Building Theatre
23 août 2018 07h05 HE | Barbara Ann Karmanos Cancer Institute
Honoring Jack D. Sobel, M.D.; Celebrating Partners silver anniversary of supporting Karmanos’ cutting-edge cancer research DETROIT, Aug. 23, 2018 (GLOBE NEWSWIRE) -- On Friday, Sept. 21, the...
Karmanos Cancer Institute-_NEW logo.jpg
Karmanos Cancer Institute hosts inaugural Prostate Cancer Awareness Game at Jimmy John’s Field, August 17
25 juil. 2018 07h05 HE | Barbara Ann Karmanos Cancer Institute
DETROIT, July 25, 2018 (GLOBE NEWSWIRE) -- The Barbara Ann Karmanos Cancer Institute, in partnership with McLaren Macomb Foundation, joins the United Shore Baseball League for the inaugural Karmanos...
Oakland_DWB_Vertical_logo
Karmanos Expands Cancer Network with Newest Location at McLaren Oakland
23 juil. 2018 10h00 HE | Barbara Ann Karmanos Cancer Institute
PONTIAC, Mich., July 23, 2018 (GLOBE NEWSWIRE) -- The Barbara Ann Karmanos Cancer Institute and McLaren Oakland announced today it will open its 15th treatment location in Michigan at McLaren...
Karmanos Weisberg Center concept rendering_2 story
Karmanos Cancer Institute to begin renovations to expand services in Farmington Hills
18 mai 2018 08h10 HE | Barbara Ann Karmanos Cancer Institute
DETROIT, May 18, 2018 (GLOBE NEWSWIRE) -- The Barbara Ann Karmanos Cancer Institute announced today it will expand its Lawrence and Idell Weisberg Cancer Treatment Center in Farmington Hills into a...
cofactor_logo.jpg
Cofactor Genomics announces new collaboration with the National Cancer Institute (NCI) to demonstrate power of RNA-based immune profiling assay
20 mars 2018 08h30 HE | Cofactor Genomics
SAN FRANCISCO, March 20, 2018 (GLOBE NEWSWIRE) -- Cofactor Genomics, leading developer of advanced RNA analysis tools, announced today that they have entered into an agreement with the National...